Biolegend, 372902, Purified anti-human CD8a Antibody, 100μg

CD8a is a 32-34 kD type I glycoprotein. It forms a homodimer (CD8a/a) or heterodimer (CD8a/b) with CD8b. CD8, also known as T8 and Leu2, is a member of the immunoglobulin superfamily found on the majority of thymocytes, a subset of peripheral blood T cells, and NK cells (which express almost exclusively CD8a homodimers). CD8 acts as a co-receptor with MHC class I-restricted T cell receptors in antigen recognition and T cell activation, and has been shown to play a role in thymic differentiation. Two domains in CD8a are important for function: the extracellular IgSF domain binds the α 3 domain of MHC class I and the cytoplasmic CXCP motif binds the tyrosine kinase p56 Lck.
100μg
Verified Reactivity: Human, Mouse, Rat
Antibody Type: Monoclonal
Host Species: Mouse
Immunogen: A 13 amino acid synthetic peptide from the C-terminal cytoplasmic domain of the alpha chain of the human CD8 molecule.
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation: The antibody was purified by affinity chromatography.
Concentration: 0.5 mg/ml
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C.
Application: IHC-P - Quality testedActiv, FC, IHC-F, WB - Reported in the literature, not verified in house
Recommended Usage: Each lot of this antibody is quality control tested by formalin-fixed paraffin-embedded immunohistochemical staining. For immunohistochemistry, a concentration range of 5.0 - 10 µg/ml is suggested. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes: Additional reported applications (for the relevant formats) include activation3, flow cytometry4, immunohistochemical staining of frozen tissue sections2, and Western blotting5.
Application References(PubMed link indicates BioLegend citation): McQuitty E, et al. 2014. J. Cutan. Pathol. 41:88. (IHC-P) Petukhova L, et al. 2010. Nature 466:113. (IHC-F) Clement M, et al. 2011. J. Immunol. 187:654. (Activ) MarTchal R, et al. 2010. BMC Cancer 10:340. (FC) Pontiggia L, et al. 2008. J. Invest. Dermatol. 129:480. (WB)
Product Citations: Cai Z, et al. 2023. Adv Sci (Weinh). 10:e2207155. PubMed Mokhtari Z, et al. 2023. Front Oncol. 13:1069696. PubMed Nickl V, et al. 2023. Cancers (Basel). 15:. PubMed Zhang W, et al. 2022. Dev Cell. 57:329. PubMed Wen J, et al. 2020. J Pathol Clin Res. 0.36875. PubMed Giadans CG, et al. 2019. J Viral Hepat. 26:727. PubMed Zheng Y, et al. 2022. iScience. 25:103785. PubMed Rye IH, et al. 2022. Mol Oncol. 16:88. PubMed Schwabenland M, et al. 2021. Immunity. . PubMed Sade–Feldman M, et al. 2018. Cell. 175:998. PubMed Chang MH, et al. 2021. Cell Rep. 37:109902. PubMed
RRID: AB_2650657 (BioLegend Cat. No. 372902)
Structure: Ig superfamily, homodimer or heterodimer with CD8β.
Distribution: Majority of thymocytes, T cell subset, NK cells.
Function: MHC class I co-receptor, thymic differentiation, T-cell activation.
Ligand/Receptor: MHC class I molecules.
Cell Type: NK cells, T cells, Thymocytes
Biology Area: Immunology
Molecular Family: CD Molecules
Antigen References: 1. McQuitty E, et al. 2014. J. Cutan. Pathol. 41:88.
Gene ID: 100387674
UniProt: View information about CD8a on UniProt.org
Clone: C8/144B
Regulatory Status: RUO
Other Names: T8, Leu2
Isotype: Mouse IgG1, κ